万邦医药 (301520)

Anhui Wanbang Pharmaceutical Technology Co.,Ltd.

ASZ

Tags

Contract Research Organization (CXO)DeepSeekWeight Loss DrugsInnovative DrugsMicro Cap StocksResearch and Experimental DevelopmentBelow IPO PriceMargin Trading and Securities LendingFood Safety

K-Line Chart

No K-line data

Stock Details

1. Key Indicators

  • Total Shares(W): 6666.67
  • Circulating A-Shares(W): 2242.30
  • Earnings Per Share(RMB): 0.5000
  • Net Assets Per Share(RMB): 22.6915
  • Operating Revenue(W RMB): 20942.59
  • Total Profit(W RMB): 3038.73
  • Net Profit Attributable to Parent(W RMB): 3311.06
  • Net Profit Growth Rate(%): -57.44
  • Weighted Return on Equity(%): 2.2100
  • Operating Cash Flow Per Share(RMB): 0.0950
  • Undistributed Profit Per Share(RMB): 5.7225
  • Capital Reserve Per Share(RMB): 15.5896

2. Main Business

The main business covers:

  • Pharmaceutical Research
  • Clinical Research Services

3. Company Basic Information

  • Company Name: Anhui Wanbang Pharmaceutical Technology Co., Ltd.
  • Listing Date: 2023-09-25
  • Industry: Research and Experimental Development
  • Address: No. 299 Huolongdi Road, High-tech Zone, Hefei City, Anhui Province
  • Website: www.ahwbyy.cn
  • Company Profile: Wanbang Pharmaceutical was established as a joint stock company through the overall transformation of Wanbang Co., Ltd. On August 6, 2019, all shareholders of Wanbang Co., Ltd. signed the "Sponsor Agreement", agreeing to convert the audited net assets of Wanbang Co., Ltd. as of May 31, 2019, which amounted to 33.3827 million yuan, into shares to establish a joint stock company. The company's share capital is 10 million yuan, with a par value of 1 yuan per share, and the portion of net assets exceeding the share capital is recorded as capital reserve. On August 22, 2019, Wanbang Pharmaceutical held its founding meeting and the first interim shareholders' meeting in 2019, where relevant proposals for the overall transformation of Wanbang Co., Ltd. into a joint stock company were reviewed and passed. For the overall transformation into a joint stock company, Wanbang Co., Ltd. hired an accounting firm and an asset appraisal agency for auditing and evaluation. According to the audit, as of May 31, 2019, the net assets of Wanbang Co., Ltd. were 33.3827 million yuan. The evaluated net asset value of Wanbang Co., Ltd. was higher than the audited net assets. On September 5, 2019, Wanbang Pharmaceutical obtained the business license (Unified Social Credit Code: 91340100784936148J) issued by the Hefei Market Supervision Administration.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Shanghai Tianyidao Investment Management Co., Ltd. - Tianyidao Shenghong Wenjian No. 7 Private Securities Investment Fund Private Securities Investment Fund 114.87 5.12

5. Concept Sectors

  • Food Safety
  • CXO Concept
  • Innovative Drugs
  • Weight Loss Drugs
  • DeepSeek
  • Margin Trading & Securities Lending
  • Micro Cap Stocks
  • Below IPO Price

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information